Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients

Journal of Medical Economics

Volumn 13, Issue 3, 2010, Pages 559-570

  Tolley, K ^a   Oliver, N ^b   Miranda, E ^b   Migliaccio Walle, K ^c   Bozkaya, D ^c   Li, Q ^c  

^a Tolley Health Economics Ltd   (United Kingdom)

^b Novartis Pharmaceuticals UK Ltd   (United Kingdom)

^c UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Cost utility; Iron chelation therapy; Myelodysplastic syndromes; QALYs

Indexed keywords

DEFERASIROX; DEFEROXAMINE;

ARTICLE; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; IRON CHELATION; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; NATIONAL HEALTH SERVICE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; UNITED KINGDOM;

BENZOIC ACIDS; COST-BENEFIT ANALYSIS; DEFEROXAMINE; ERYTHROCYTE TRANSFUSION; GREAT BRITAIN; HUMANS; INSURANCE CLAIM REVIEW; IRON CHELATING AGENTS; IRON OVERLOAD; LONGITUDINAL STUDIES; MYELODYSPLASTIC SYNDROMES; QUALITY-ADJUSTED LIFE YEARS; SIDEROPHORES; STATE MEDICINE; SURVIVAL ANALYSIS; TRIAZOLES;

EID: 77956712811     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.516203     Document Type: Article

References (52)

1. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008;88:24-29
2. Wells RA, Leber B, Buckstein R, et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk Res 2008;32:1338-1353
3. Srinivasan S, Schiffer CA. Current treatment options and strategies for myelodysplastic syndromes. Expert Opin Pharmacother 2008;9:1667-1678
4. Frytak JR, Henk HJ, De Castro CM, et al. Estimation of economic costs associated with transfusion dependence in adults with MDS. Curr Med Res Opin 2009;25:1941-1951
5. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-7603
6. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008;83:858-861
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™: Myelodysplastic Syndromes. 1-31 2008. www.nccn.org
8. Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 2010; 34:864-870
9. Fox F, Kundgen A, Nachtkamp K, et al. Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy alone. Blood (ASH meeting abstracts) 114, 2009
10. Raptis A, Duh MS, Wang ST, et al.Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multi-center clinical practices. Transfusion 2009
11. Leitch HA, Wong DHC, Leger CS, et al. Improved leukaemia-free and overall survival in patients with myelodysplastic syndrome receiving iron chelation therapy: a subgroup analysis. Abstract 1469. 49th American Society of Haematology meeting, Atlanta Georgia USA, 8-11th December, 2007
12. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302
13. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-3462
14. Swedish Orphan International Ltd. Ferriprox Summary of Product Characteristics, 2008
15. Novartis Pharmaceuticals. Opinions of three UK clinicians treating MDS patients. Data on file, 2009
16. Karnon J, Tolley K, Oyee J, et al. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin 2008; 24:1609-1621
17. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2009; 95:557-566
18. Schmid M, Guerci-Bresier A, Porta MD, et al. Deferasirox (Exjade®) is effective and well tolerated in chelation-naive and previously chelated patients with transfusion-dependent myelodysplastic syndromes (MDS). Abstract 3806. 51st American Society of Haematology meeting, New Orleans, LA, USA, 6-9th December, 2009
19. List A, Baer M, Steensma D, et al. Two-year analysis of efficacy and safety of deferasirox (Exjade®) treatment in myelodysplastic syndrome patients enrolled in the US03 study. Abstract 3829. 51st American Society of Haematology meeting, New Orleans, LA, USA, 6-9th December, 2009
20. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088
21. Novartis Pharmaceuticals UK Ltd. Deferasirox summary of product characteristics. 2009. http://emc.medicines.org.uk/
22. Novartis Pharmaceuticals UK Ltd. Desferrioxamine summary of product characteristics. http://emc.medicines.org.uk/
23. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136:501-508
24. Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol 2007;82:1136-1139
25. Glanville J, Eleftheriou P, Porter J. MRI evidence of cardiac iron accumulation in myelodysplasia and unusual anaemias. Blood (ASH annual meeting abstracts) 108, 2006
26. Rose C. Iron chelation therapy improves survival in regularly transfused MDS Patients. A prospective analysis by the GFM. Slides presented at American Society of Haematology (ASH) meeting 2007 Data on file, 2007
27. Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Abstract 249, 49th American Society of Haematology meeting, Atlanta Georgia USA, 8-11th December, 2007
28. Novartis Pharmaceuticals. Western General Hospital data on MDS. Personal correspondence data on file, 2008
29. Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukaemic evolution in patients with myelodysplastic syndrome. Blood (American Society of Haematology Annual Meeting Abstracts) 2008 112: Abstract 640, 2008
30. Jaeger M, Aul C, Sohngen D, et al. Iron overload in polytransfused patients with MDS: Use of L1 for oral iron chelation. Drugs Today 1992;28(Suppl A): 143-147
31. Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin 2009;25:139-147
32. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or desferroxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007;29:909-917
33. Porter JB, Bowden D, GanserA, et al.Satisfaction and adherence significantly improves in patients with thalassaemia and myelodysplastic syndromes treated with deferasirox (Exjade®). Abstract 1306. 50th American Society of Haematology meeting, San Francisco, California USA, 6-9th December, 2008
34. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13:89-102
35. Wong JB, Koff RS, Tine F, et al. Cost effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-675
36. Barr R, Furlong W, Henwood J, et al. Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol 1996;14:1413-1420
37. British National Formulary 59. March 2010. Deferasirox. http://bnf.org/bnf/bnf/59/129929.htm?q=exjade&t=search&ss=text&p= 1#-129929
38. Sourced from Chemist and Druggist website 26/02/2010. http://www.chemistanddruggist.co.uk/
39. Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002;162:1597-1603
40. Luengo-Fernandez R, Leal J, Gray A, et al. Cost of cardiovascular diseases in the United Kingdom. Heart 2006;92:1384-1389
41. Diabetes UK. Diabetes. Beware the silent assassin. A report from Diabetes UK, October 2008. http://www.diabetes.org.uk/Documents/Reports/Silent-assassin- press-report.pdf
42. Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007; 11:1-205
43. Varney SJ, Guest JF. The annual cost of blood transfusions in the UK. Transfus Med 2003;13:205-218
44. National Institute of Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. June 2008
45. Desrosiers MP, Payne K, Proskorovsky I, et al. Estimated total annual costs of infused iron chelation therapy in the United Kingdom. Poster 0810. 11th Congress of the European Haematology Association, Amsterdam, The Netherlands, 15-18th June 2006
46. Delea TE, Sofrygin O, Thomas SK, et al. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics 2007;25:329-342
47. The Scottish Medicines Consortium (SMC). Guidance to Manufacturers for completion of New Product Assessment Form (NPAF) (Clinical and Economic Sections combined). 2010. Available from: URL: http://www.scottishmedicines.org.uk/
48. Abetz L, Baladi JF, Jones P, et al. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes 2006;4:73
49. Taher A, Cappellini MD. Update on the use of deferasirox in the management of iron overload. Ther Clin Risk Manag 2009;5:857-868
50. Porter JB, Bowden D, GanserA, et al.Improved health-related quality of life in patients with haematological disorders receiving deferasirox (Exjade®). Blood (American Society of Haematology Annual Meeting Abstracts) 2008 112. Abstract 1307
51. Osborne RH, De Abreu LR, Dalton A, et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health 2007; 10:451-456
52. Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur J Clin Pharmacol 2001;56:915-922